Park M, Kim D, Ko S, Kim A, Mo K, Yoon H (2022) Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci 23:6806. https://doi.org/10.3390/ijms23126806
Article CAS PubMed PubMed Central Google Scholar
Trayes KP, Cokenakes SEH (2021) Breast cancer treatment. Am Fam Physician 104:171–178
Huang J, Chan PS, Lok V, Chen X, Ding H, Jin Y, Yuan J, Lao X-Q, Zheng Z-J, Wong MC (2021) Global incidence and mortality of breast cancer: a trend analysis. Aging 13:5748–5803. https://doi.org/10.18632/aging.202502
Article PubMed PubMed Central Google Scholar
Katsura C, Ogunmwonyi I, Kankam HK, Saha S (2022) Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond) 83:1–7. https://doi.org/10.12968/hmed.2021.0459
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–333. https://doi.org/10.3322/caac.21708
Orea-Soufi A, Paik J, Bragança J, Donlon TA, Willcox BJ, Link W (2022) FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci 43:1070–1084. https://doi.org/10.1016/j.tips.2022.09.010
Article CAS PubMed Google Scholar
Farhan M, Wang H, Gaur U, Little PJ, Xu J, Zheng W (2017) FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci 13:815–827. https://doi.org/10.7150/ijbs.20052
Article CAS PubMed PubMed Central Google Scholar
Zanella F, Santos NRD, Link W (2013) Moving to the core: spatiotemporal analysis of Forkhead box O (FOXO) and nuclear factor-κB (NF-κB) nuclear translocation. Traffic 14:247–258. https://doi.org/10.1111/tra.12034
Article CAS PubMed Google Scholar
Peng S, Li W, Hou N, Huang N (2020) A review of FOXO1-regulated metabolic diseases and related drug discoveries. Cells 9:184. https://doi.org/10.3390/cells9010184
Article CAS PubMed PubMed Central Google Scholar
Gui T, Burgering BMT (2022) FOXOs: masters of the equilibrium. FEBS J 289:7918–7939. https://doi.org/10.1111/febs.16221
Article CAS PubMed Google Scholar
Zou Y, Lin X, Bu J, Lin Z, Chen Y, Qiu Y, Mo H, Tang Y, Fang W, Wu Z (2020) Timeless-stimulated miR-5188-FOXO1/β-catenin-c-Jun feedback loop promotes stemness via ubiquitination of β-Catenin in breast cancer. Mol Ther 28:313–327. https://doi.org/10.1016/j.ymthe.2019.08.015
Article CAS PubMed Google Scholar
Parikh K, Cang S, Sekhri A, Liu D (2014) Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents. J Hematol Oncol 7:78. https://doi.org/10.1186/s13045-014-0078-0
Article CAS PubMed PubMed Central Google Scholar
Jimenez L, Mayoral-Varo V, Amenábar C, Ortega J, Sequeira JGN, Machuqueiro M, Mourato C, Silvestri R, Angeli A, Carta F, Supuran CT, Megías D, Ferreira BI, Link W (2022) Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1-mediated nuclear export. Traffic 23:587–599. https://doi.org/10.1111/tra.12872
Article CAS PubMed PubMed Central Google Scholar
Shi Y, Xu S, Li S (2022) Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer. Mol Cell Endocrinol 545:111558. https://doi.org/10.1016/j.mce.2022.111558
Article CAS PubMed Google Scholar
Cautain B, Castillo F, Musso L, Ferreira BI, Pedro Nd, Quesada LR, Machado S, Vicente F, Dallavalle S, Link W (2016) Discovery of a novel, isothiazolonaphthoquinone-based small molecule activator of FOXO nuclear-cytoplasmic shuttling. PLoS ONE 11:e0167491. https://doi.org/10.1371/journal.pone.0167491
Article CAS PubMed PubMed Central Google Scholar
Uddin MH, Zonder JA, Azmi AS (2020) Exportin 1 inhibition as antiviral therapy. Drug Discov Today 25:1775–1781. https://doi.org/10.1016/j.drudis.2020.06.014
Article CAS PubMed PubMed Central Google Scholar
Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, Zhou Z, Shu G, Yin G (2022) Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther 7:3. https://doi.org/10.1038/s41392-021-00762-6
Article CAS PubMed PubMed Central Google Scholar
Varma K, Chauhan A, Bhargava M, Misra V, Srivastava S (2020) Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma. Indian J Pathol Microbiol 63:13–18. https://doi.org/10.4103/IJPM.IJPM_419_19
Essers MAG, Vries-Smits LMMd, Barker N, Polderman PE, Burgering BMT, Korswagen HC (2005) Stress signaling functional interaction between -catenin and FOXO in oxidative. Science 308:1181–1184. https://doi.org/10.1126/science.1109083
Article CAS PubMed Google Scholar
Ip W, Chiang Y-TA, Jin T (2012) The involvement of the Wnt signaling pathway and TCF7L2 in diabetes mellitus: the current understanding, dispute, and perspective. Cell Biosci 2:28. https://doi.org/10.1186/2045-3701-2-28
Article CAS PubMed PubMed Central Google Scholar
Lin X, Zuo S, Luo R, Li Y, Yu G, Zou Y, Zhou Y, Liu Z, Liu Y, Hu Y, Xie Y, Fang W, Liu Z (2019) HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma. Theranostics 9:7583–7598. https://doi.org/10.7150/thno.37717
Article CAS PubMed PubMed Central Google Scholar
Guan H, Tan P, Xie L, Mi B, Fang Z, Li J, Yue J, Liao H, Li F (2015) FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression. Oncogenesis 7:e166. https://doi.org/10.1038/oncsis.2015.25
Ling J, Wang F, Liu C, Dong X, Xue Y, Jia X, Song W, Li Q (2019) FOXO1-regulated lncRNA LINC01197 inhibits pancreatic adenocarcinoma cell proliferation by restraining Wnt/β-catenin signaling. J Exp Clin Cancer Res 38:179. https://doi.org/10.1186/s13046-019-1174-3
Article PubMed PubMed Central Google Scholar
Zhang L-Y, Chen Y, Jia J, Zhu X, He Y, Wu L-M (2019) MiR-27a promotes EMT in ovarian cancer through active Wnt/. Cancer Biomark 24:31–42. https://doi.org/10.3233/CBM-181229
Article CAS PubMed Google Scholar
Wang Y, Wang Q, Li X, Luo G, Shen M, Shi J, Wang X, Tang L (2021) Paeoniflorin sensitizes breast cancer cells to tamoxifen by downregulating microRNA-15b via the FOXO1/CCND1/β-catenin axis. Drug Des Devel Ther 15:245–257. https://doi.org/10.2147/DDDT.S278002
Article PubMed PubMed Central Google Scholar
Tenbaum SP, Ordóñez-Morán P, Isabel Puig IC, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Cajal SRY, Schwartz S Jr, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Palmer HG (2012) β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18:892–901. https://doi.org/10.1038/nm.2772
Comments (0)